Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.

@article{Shafee2008CancerSC,
  title={Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.},
  author={Norazizah Shafee and Christopher E. Smith and Shuanzeng Wei and Yoon Kim and Gordon B. Mills and Gabriel N Hortobagyi and Eric John Stanbridge and Eva Y-H P Lee},
  journal={Cancer research},
  year={2008},
  volume={68 9},
  pages={3243-50}
}
The majority of BRCA1-associated breast cancers are basal cell-like, which is associated with a poor outcome. Using a spontaneous mouse mammary tumor model, we show that platinum compounds, which generate DNA breaks during the repair process, are more effective than doxorubicin in Brca1/p53-mutated tumors. At 0.5 mg/kg of daily cisplatin treatment, 80% primary tumors (n = 8) show complete pathologic response. At greater dosages, 100% show complete response (n = 19). However, after 2 to 3 months… CONTINUE READING
111 Citations
32 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 111 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Similar Papers

Loading similar papers…